Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline
| Autor: | Eystein S Husebye, Frederik Castinetti, Sherwin Criseno, Giuseppe Curigliano, Brigitte Decallonne, Maria Fleseriu, Claire E Higham, Isabella Lupi, Stavroula A Paschou, Miklos Toth, Monique van der Kooij, Olaf M Dekkers |
|---|---|
| Přispěvatelé: | Haukeland University Hospital, University of Bergen (UiB), Marseille medical genetics - Centre de génétique médicale de Marseille (MMG), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Marseille Maladies Rares (MarMaRa), Aix Marseille Université (AMU), Service d'endocrinologie, diabète, maladies métaboliques [Hôpital de la Conception - APHM], University Hospitals Birmingham [Birmingham, Royaume-Uni], Università degli Studi di Milano = University of Milan (UNIMI), University Hospitals Leuven [Leuven], Oregon Health and Science University [Portland] (OHSU), University of Manchester [Manchester], Pisa University Hospital, National and Kapodistrian University of Athens (NKUA), Semmelweis University [Budapest], Leiden University Medical Center (LUMC), Universiteit Leiden |
| Jazyk: | angličtina |
| Rok vydání: | 2022 |
| Předmět: |
Endocrinology
Drug-Related Side Effects and Adverse Reactions Neoplasms Endocrinology Diabetes and Metabolism Humans General Medicine [SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolism Hypophysitis Endocrine System Diseases Immune Checkpoint Inhibitors [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| Zdroj: | European Journal of Endocrinology (EJE) G1-G21 European Journal of Endocrinology European Journal of Endocrinology, 2022, 187 (6), pp.G1-G21. ⟨10.1530/EJE-22-0689⟩ |
| ISSN: | 0804-4643 1479-683X |
| Popis: | Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but are associated with significant autoimmune endocrinopathies that pose both diagnostic and treatment challenges. The aim of this guideline is to provide clinicians with the best possible evidence-based recommendations for treatment and follow-up of patients with ICI-induced endocrine side-effects based on the Grading of Recommendations Assessment, Development, and Evaluation system. As these drugs have been used for a relatively short time, large systematic investigations are scarce. A systematic approach to diagnosis, treatment, and follow-up is needed, including baseline tests of endocrine function before each treatment cycle. We conclude that there is no clear evidence for the benefit of high-dose glucocorticoids to treat endocrine toxicities with the possible exceptions of severe thyroid eye disease and hypophysitis affecting the visual apparatus. With the exception of thyroiditis, most endocrine dysfunctions appear to be permanent regardless of ICI discontinuation. Thus, the development of endocrinopathies does not dictate a need to stop ICI treatment. ispartof: EUROPEAN JOURNAL OF ENDOCRINOLOGY vol:187 issue:6 pages:G1-G21 ispartof: location:England status: published |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|